Concert’s CTP-543 Shows Advantages Over Lilly, Pfizer Candidates For Alopecia
Executive Summary
Concert’s deuterated ruxolitinib analog is potentially third in line to market for alopecia areata, behind Lilly’s Olumiant and a Pfizer JAK3 inhibitor, but may be demonstrating a best-in-class profile.
You may also be interested in...
Sun Eyes Big Stage For Concert’s Alopecia Asset
Sun outlines contours of path ahead for deuruxolitinib, which came to it via the recent $576m Concert deal and pits it against Eli Lilly's Olumiant and Pfizer's investigational candidate ritlecitinib. The Indian firm is believed to have had the JAK 1/2 inhibitor on its radar since August last year.
Sun Eyes Big Stage For Concert’s Alopecia Asset
Sun outlines contours of path ahead for deuruxolitinib, which came to it via the recent $576m Concert deal and pits it against Eli Lilly's Olumiant and Pfizer's investigational candidate ritlecitinib. The Indian firm is believed to have had the JAK 1/2 inhibitor on its radar since August last year.
Sun Pharma Will Take Concert’s Alopecia Drug The Rest Of The Way
Coming up after Lilly’s Olumiant and Pfizer’s ritlecitinib in alopecia areata, deuterated ruxolitinib is said to offer a differentiated profile including patient-reported outcomes data.